Kimberly-Clark Corporation
Explore Kimberly-Clark Corporation
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Kimberly-Clark Corporation
Explore Kimberly-Clark Corporation
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2025 Revenue
$16.4B
▼ 15.7% vs FY2024 ($19.5B)
Source: Annual report / company filing
Kimberly-Clark Corporation reported $16.4B in revenue for fiscal year 2025. This represents a decline of 15.7% compared to the 2024 figure of $19.5B.
The single most clarifying financial fact about Kimberly-Clark is that its gross margin in fiscal year 2024 reached 34.2% despite extreme volatility in global fluff pulp and energy prices — the two input costs that most directly threaten a tissue manufacturer's economics. That margin stability is not accidental. It reflects a hedging program and a premium product mix shift toward higher-margin variants that the company has been executing systematically. Net sales held at $16.4B in FY2025, matching the $19.5 billion reported in FY2022 and recovering from the $19.3 billion posted in FY2023. The revenue base is not growing quickly, but it is not shrinking either — a pattern consistent with a company operating in mature categories with strong brand positions but limited pricing elasticity. Net income reached $1.5 billion against $19.5 billion in sales, a net margin of approximately 7.7%. The Personal Care segment, which houses Huggies and Depend, generates the highest gross margins in the portfolio at approximately 38%, creating a meaningful mix-benefit when that segment outperforms the tissue business. The company's market capitalization of $42 billion, against $19.5 billion in revenue, reflects a premium multiple that investors assign to businesses with durable category positions. Kimberly-Clark has paid dividends continuously for more than 50 years. That consistency matters to a specific class of investor, and that investor base provides a stable ownership structure that gives management the freedom to invest in long-cycle manufacturing improvements rather than optimizing for quarterly results.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $16.4B | — | -15.7% |
| FY2024 | $19.5B | $1.5B | +1.0% |
| FY2023 | $19.3B | — | -1.0% |
| FY2022 | $19.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.